You are here

P&T® Journal contents for March 2007


The author summarizes the efficacy of two inhaled agents—ipratropium bromide (Atrovent HFA) and tiotropium bromide (Spiriva)—in reducing dyspnea, bronchoconstriction, the frequency of disease exacerbation, and in improving patients’ health status.
Daren L. Knoell, MD
Meeting Highlights
Two biologic agents are featured: infliximab (Remicade), which is approved for the treatment of ulcerative colitis, and adalimumab (Humira), indicated for patients with Crohn’s disease.
Walter Alexander
The author discusses paliperidone (Invega) for the treatment of schizophrenia; telbivudine (Tyzeka) for patients with chronic hepatitis B infection; and a combination of clindamycin phosphate and tretinoin (Ziana Gel) as a topical therapy for acne vulgaris.
Marvin M. Goldenberg, PhD, RPh, MS
Continuing Education Credit
Geriatric depression is often overlooked. The authors review the epidemiology, diagnosis, pathophysiology, and treatment of depression in older adults, with an emphasis on newer pharmacotherapeutic agents.
Richard B. Birrer, MD, Michael DeLisi, MD, and Talin Arsen Dadoyan, MD


David Nash, MD, MBA, discusses the Institute of Medicine’s recommendations for a national P4P program for the entire Medicare system.
David B. Nash, MD, MBA
Medication Errors
Matthew Grissinger, RPh, FASCP, explains how injecting medications too rapidly can harm patients.
Matthew Grissinger, RPh, FASCP
Prescription: Washington
Stephen Barlas discusses some of the challenges that lie ahead at the FDA when Congress reauthorizes the Prescription Drug Users Fee Act, which expires in June.
Stephen Barlas
P&T presents the latest studies and information about FDA approvals, drug indications, industry updates, and new devices.
Drug Forecast
The author reviews conivaptan HCl injection (Vaprisol) for the treatment of euvolemic hyponatremia.
Larisa Chagan, PharmD, BCPS